← SIBO

Causes, Symptoms, and Natural Treatment Approaches

What small intestinal bacterial overgrowth is, why it causes bloating and digestive distress, and evidence-based strategies for treatment

SIBO — small intestinal bacterial overgrowth — happens when bacteria that belong in your colon migrate upward and colonize the small intestine in large numbers. The result is bloating that starts within an hour of eating, gas, cramping, alternating constipation and diarrhea, and in chronic cases, nutritional deficiencies from impaired absorption. An estimated 6–15% of healthy people have SIBO; among those diagnosed with IBS, the proportion may exceed 50% [2]. Most people with SIBO have been told they have IBS and treated for years without addressing the root cause.

What Goes Wrong in SIBO

Your small intestine is supposed to be nearly sterile. The stomach's acid, bile from the gallbladder, pancreatic enzymes, and the rhythmic muscular contractions of the migrating motor complex (MMC) — which sweep residual bacteria toward the colon every 90 minutes during fasting — all work together to keep bacterial counts low in the upper gut [1].

When any of these defenses fail, bacteria proliferate where they shouldn't. They ferment carbohydrates before your body can absorb them, producing hydrogen and methane gas. This fermentation also damages the microvilli (the finger-like projections that absorb nutrients), impairing absorption of fats, fat-soluble vitamins (A, D, E, K), vitamin B12, and iron [1].

There are two main gas profiles in SIBO that tend to produce different symptoms:

  • Hydrogen-dominant SIBO — typically associated with diarrhea, caused by bacteria like Escherichia coli and Klebsiella
  • Methane-dominant SIBO (IMO) — technically caused by archaea rather than bacteria; methane slows gut motility and is strongly associated with constipation

Some people have both types simultaneously, and the treatment response differs between them [1].

Common Root Causes

SIBO is almost never idiopathic — there is almost always an underlying reason that the normal clearing mechanisms failed [1]:

Low stomach acid (hypochlorhydria): Stomach acid is the first line of defense. Long-term use of proton pump inhibitors (PPIs) significantly increases SIBO risk — multiple studies have found 2–7x higher prevalence in PPI users versus non-users.

Impaired MMC: The migrating motor complex is the intestine's housekeeping mechanism during fasting. Anything that disrupts it — including a prior food poisoning episode (especially with Campylobacter, Salmonella, or E. coli) — can leave the gut sluggish and prone to bacterial buildup. Post-infectious SIBO is one of the most common presentations.

Anatomical factors: Adhesions from surgery, endometriosis scarring, or structural abnormalities can create stagnant pockets where bacteria pool.

Underlying conditions: Hypothyroidism (slows gut motility), diabetes (autonomic neuropathy affects the gut), celiac disease, Crohn's disease affecting the ileocecal valve, and chronic use of narcotic pain medications all raise SIBO risk [2].

How SIBO Is Diagnosed

The standard diagnostic tool is the lactulose or glucose breath test. You drink a sugar solution; if bacteria in the small intestine ferment it, they produce hydrogen or methane gases that are absorbed, enter the bloodstream, pass to the lungs, and appear in your exhaled breath. A rise of 20+ ppm hydrogen within 90 minutes (or any methane elevation above 10 ppm) is considered positive [1].

Breath testing has limitations — sensitivity and specificity vary by protocol and lab — but it's non-invasive, accessible, and captures both hydrogen and methane producers. Some practitioners use small bowel aspirate culture (direct sampling via endoscopy) as the gold standard, but this is rarely done in practice due to cost and invasiveness [1].

Dietary Approaches to SIBO

Diet does not cure SIBO but can significantly reduce symptoms and help antimicrobial treatments work more effectively.

The elemental diet is the most aggressive dietary approach — a two-week course of pre-digested nutrients (amino acids, simple sugars, fats, vitamins) that are absorbed so completely in the upper small intestine that bacteria in the lower small intestine are essentially starved. A landmark study found that 14 days of elemental diet normalized the lactulose breath test in 80% of participants — a success rate comparable to antibiotic treatment [4]. The elemental diet is difficult to follow and nutritionally monotonous, but it can be a powerful intervention when other treatments have failed or when someone wants to avoid antibiotics.

Low-FODMAP diet reduces fermentable carbohydrates that feed small intestinal bacteria, providing symptom relief while you treat the underlying overgrowth. It does not eradicate SIBO but reduces the fermentation load, easing bloating, gas, and cramping during treatment.

Specific Carbohydrate Diet (SCD) and GAPS take a different approach — eliminating disaccharides and complex starches while allowing monosaccharides — and some patients report significant improvement, though controlled evidence is limited.

Herbal Antimicrobials

A well-designed 2014 clinical trial compared herbal antimicrobial protocols directly against rifaximin — the gold-standard antibiotic used for SIBO — with striking results. Participants received either rifaximin (1200 mg/day for 4 weeks) or a combination of herbal antimicrobials. Breath test normalization occurred in 46% of the rifaximin group and 57% of the herbal group — a statistically non-inferior result. Among those who failed rifaximin, 57% subsequently responded to herbals [3].

The herbal protocols used in the trial included formulations containing:

  • Oregano oil (carvacrol) — broad-spectrum antimicrobial with demonstrated activity against gram-positive and gram-negative bacteria
  • Berberine — an alkaloid from goldenseal and barberry with strong antimicrobial and motility-supporting effects
  • Neem — traditionally used for gut infections; contains nimbin and nimbidin compounds with broad antimicrobial activity
  • Allicin (garlic extract) — particularly active against hydrogen sulfide-producing bacteria and methane-producing archaea

These herbals can be used individually or in combination. Because they have broader antimicrobial activity than rifaximin (which is specific to hydrogen-type SIBO), they may be especially useful for methane-dominant presentations where rifaximin alone is less effective [3].

Rifaximin and Antibiotic Treatment

Rifaximin is a non-absorbable antibiotic that stays in the gut, making it effective against intestinal bacteria with minimal systemic side effects. The 2021 meta-analysis covering 26 studies found rifaximin achieved SIBO eradication (breath test normalization) in approximately 49–73% of cases depending on dose and duration, with hydrogen-type SIBO responding better than methane-dominant [5]. For methane-dominant SIBO, rifaximin is often combined with neomycin or metronidazole.

The limitation of antibiotics is recurrence. Without addressing the root cause — whether that's low stomach acid, impaired MMC, a motility disorder, or another underlying condition — most people relapse within months. Treating SIBO once without treating why it developed leads to a cycle of repeated antibiotic courses.

Motility Support After Treatment

One of the most important and often overlooked aspects of SIBO management is restoring the migrating motor complex after treatment. Pro-kinetic agents — compounds that stimulate the MMC — can significantly reduce relapse rates.

Natural motility-supporting options include:

  • Ginger — stimulates gastric emptying and migrating motor complex activity; used as a pro-kinetic in some functional medicine protocols
  • 5-HTP — a serotonin precursor (95% of the body's serotonin is in the gut, where it regulates motility)
  • Low-dose naltrexone (LDN) — used off-label to stimulate gut motility in some clinical settings

Prokinetic herbs and pharmaceuticals are typically taken at bedtime so they work during the fasting period when the MMC should be most active.

The SIBO-Leaky Gut Connection

SIBO and intestinal permeability ("leaky gut") are closely linked. Bacterial overgrowth produces lipopolysaccharides (LPS) — toxins from gram-negative bacterial cell walls — that damage tight junctions in the intestinal epithelium, allowing bacterial fragments and undigested food particles to enter the bloodstream. A 2021 study measuring intestinal barrier markers in SIBO patients found that treating SIBO with rifaximin significantly improved intestinal barrier integrity — diamine oxidase (DAO) and D-lactic acid levels both normalized after eradication [6].

This means SIBO may be both a consequence of gut damage (when the protective mechanisms fail) and a cause of further gut damage (as overgrown bacteria erode the barrier). Healing SIBO is often a necessary step in resolving other gut-linked conditions, including histamine intolerance, multiple food sensitivities, and systemic inflammation.

See our Leaky Gut page for more on intestinal permeability and repair strategies, and our Histamine Intolerance page for how SIBO contributes to histamine accumulation.

Evidence Review

Diagnostic Framework and Clinical Guidelines

The authoritative foundation for SIBO diagnosis and treatment is the 2020 ACG Clinical Guideline (Pimentel et al., PMID 32023228, American Journal of Gastroenterology). This practice guideline from the American College of Gastroenterology synthesizes the full evidence base to date, defining SIBO as "a condition associated with a broad array of GI and extra-intestinal symptoms" caused by excess bacteria in the small intestine. Key guideline recommendations include: glucose breath testing as preferred over lactulose (higher specificity, lower false-positive rate), rifaximin as first-line pharmacological treatment for hydrogen-SIBO, and rifaximin plus neomycin for methane-dominant SIBO (IMO). The guideline acknowledges that "patients who fail antibiotic therapy may be treated with herbal therapy" — a significant clinical acknowledgment given the 2014 herbal vs. rifaximin trial. Notably, the guidelines emphasize that SIBO recurrence is common and that identification and treatment of the predisposing cause is essential.

SIBO-IBS Overlap

Ghoshal, Shukla, and Ghoshal (2017, PMID 28274108, Gut and Liver) performed a systematic review of the literature connecting SIBO and IBS. They found that in pooled data from multiple studies, SIBO prevalence in IBS patients ranged from 4% to 78%, with the wide range attributable to differing diagnostic criteria and breath test protocols. Meta-analyses consistently found that treating SIBO with antibiotics (primarily rifaximin) improved overall IBS symptoms — particularly bloating and diarrhea. The proposed mechanism: excess bacteria ferment undigested carbohydrates, producing gas and altering gut motility, fluid secretion, and visceral sensitivity — mimicking the IBS symptom picture. The review argues that SIBO and IBS are not separate diseases but overlapping conditions, with SIBO being one of the functional mechanisms underlying IBS in a substantial subset of patients.

Herbal vs. Rifaximin: The Key Trial

Chedid et al. (2014, PMID 24891990, Global Advances in Health and Medicine) conducted the only direct head-to-head comparison of herbal antimicrobials versus rifaximin for SIBO. 104 patients with positive lactulose breath tests were randomized to: (a) rifaximin 1200 mg/day for 28 days, or (b) one of two commercially available herbal antimicrobial protocols (FC Cidal/Dysbiocide or Candibactin-AR/BR). Primary outcome: breath test normalization at 4 weeks. Results: rifaximin 46.1% normalization vs. herbal 56.8% — the herbal protocols achieved numerically higher eradication rates, and the difference was statistically non-inferior (p=0.24 for non-inferiority). Among 14 patients who failed rifaximin and subsequently received herbal therapy, 8 of 14 (57%) normalized. The herbal protocols contained combinations including oregano oil, berberine, coptis, neem, and other botanical antimicrobials. This trial is foundational to the functional medicine approach to SIBO and provides Level II evidence (single RCT) for herbal treatment equivalence.

Elemental Diet Evidence

Pimentel et al. (2004, PMID 14992438, Digestive Diseases and Sciences) examined the elemental diet as a non-antibiotic SIBO treatment. 93 patients with positive lactulose breath tests received a commercially prepared elemental formula (Vivonex Plus) for 14 days. Breath test normalization — the primary outcome — occurred in 80.3% of participants. This is a high response rate compared to typical antibiotic outcomes (often 50–65% for a single course). The proposed mechanism: elemental formulas containing free amino acids, glucose, and fatty acids are absorbed so rapidly and completely in the proximal small intestine that insufficient substrate reaches the bacteria colonizing the more distal small bowel, effectively starving them. Limitations: no control arm (no placebo or comparison group), single-center, and compliance with a 14-day liquid diet is a significant practical challenge. Despite these limitations, this study is widely cited as support for elemental diet as a primary or rescue SIBO treatment.

Rifaximin Efficacy: Meta-Analysis

Wang, Zhang, and Hou (2021, PMID 34767484, Expert Review of Gastroenterology and Hepatology) performed a systematic review and meta-analysis of rifaximin for SIBO eradication, analyzing 26 eligible studies. Pooled eradication rate: approximately 49% (95% CI varies by analysis) for hydrogen-dominant SIBO. Methane-dominant presentations (now reclassified as intestinal methanogen overgrowth, or IMO) responded less well to rifaximin alone. Rifaximin plus neomycin combination achieved approximately 87% eradication in methane-positive patients in several of the included studies. Rifaximin was well-tolerated across studies, with adverse event rates comparable to placebo — a significant safety advantage. The review also noted substantial study heterogeneity in diagnostic criteria, rifaximin dosing (ranging from 800–2400 mg/day), and treatment duration (7–14 days), making precise pooled estimates difficult.

SIBO and Intestinal Barrier Function

Yang et al. (2021, PMID 34306403, American Journal of Translational Research) measured markers of intestinal barrier integrity in SIBO patients before and after rifaximin treatment. Pre-treatment, SIBO patients showed elevated serum D-lactic acid (a bacterial metabolite that enters circulation through a damaged gut barrier) and reduced serum DAO (produced by intestinal epithelial cells; lower levels indicate epithelial damage). Following rifaximin eradication, both markers normalized: DAO activity increased and D-lactic acid decreased significantly. These are functional markers of intestinal barrier restoration — suggesting that eliminating the bacterial overgrowth directly reduces the permeability-driving insult. This study provides mechanistic support for the clinical observation that treating SIBO can improve systemic symptoms beyond just the gut.

Evidence Strength Assessment

The evidence for rifaximin treatment of hydrogen-dominant SIBO is strong: multiple RCTs, systematic reviews, and clinical guidelines support it as first-line therapy, with consistent eradication rates of 40–73%.

The evidence for herbal antimicrobials is promising: the 2014 Chedid trial provides Level II evidence for non-inferiority to rifaximin, though replication in larger trials is needed.

The evidence for elemental diet is moderate: a single large uncontrolled trial showing 80% eradication, not replicated in RCT format.

The evidence for motility support reducing recurrence is theoretically strong but clinically underexplored — few rigorous RCTs have specifically tested prokinetic agents for SIBO relapse prevention, though this is standard of care in functional medicine practice.

The evidence for SIBO causing intestinal permeability is mechanistically coherent and supported by biomarker data (Yang et al.), but lacks large prospective studies directly measuring barrier function before and after SIBO treatment.

References

  1. ACG Clinical Guideline: Small Intestinal Bacterial OvergrowthPimentel M, Saad RJ, Long MD, Rao SSC. American Journal of Gastroenterology, 2020. PubMed 32023228 →
  2. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic DichotomyGhoshal UC, Shukla R, Ghoshal U. Gut and Liver, 2017. PubMed 28274108 →
  3. Herbal Therapy Is Equivalent to Rifaximin for the Treatment of Small Intestinal Bacterial OvergrowthChedid V, Dhalla S, Clarke JO, Roland BC, Dunbar KB, Koh J, Justino E, Tomakin E, Mullin GE. Global Advances in Health and Medicine, 2014. PubMed 24891990 →
  4. A 14-Day Elemental Diet Is Highly Effective in Normalizing the Lactulose Breath TestPimentel M, Constantino T, Kong Y, Bajwa M, Rezaei A, Park S. Digestive Diseases and Sciences, 2004. PubMed 14992438 →
  5. Efficacy of Rifaximin in Treating Small Intestine Bacterial Overgrowth: A Systematic Review and Meta-AnalysisWang J, Zhang L, Hou X. Expert Review of Gastroenterology and Hepatology, 2021. PubMed 34767484 →
  6. Small Intestinal Bacterial Overgrowth and Evaluation of Intestinal Barrier Function in Patients with Ulcerative ColitisYang C, Zhang X, Wang S, Huo X, Wang J. American Journal of Translational Research, 2021. PubMed 34306403 →

Weekly Research Digest

Get new topics and updated research delivered to your inbox.